J. Alsolaiss

Exploring the utility of ssDNA aptamers directed against snake venom toxins as new therapeutics for tropical snakebite envenoming

This study identifies ssDNA aptamers that inhibit snake venom toxins and show comparable efficacy to antivenoms in vitro and ex vivo.

Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: results of preclinical efficacy testing

This study evaluates two antivenoms as alternatives to SAIMR Polyvalent in Eswatini, finding they are equally or more effective against the most common snake venom but less effective against others.

Exploring the utility of recombinantly expressed snake venom serine protease toxins as immunogens for generating experimental snakebite antivenoms

This study evaluates recombinant snake venom serine protease toxins as immunogens to generate antivenoms that target specific venom-induced pathologies.

In vitro and in vivo venom-inhibition assays identify metalloproteinase-inhibiting drugs as potential treatments for snakebite envenoming by Dispholidus typus

This study evaluates four SVMP inhibitors for treating D. typus snakebite envenoming, finding DMPS and marimastat effective in preclinical models.

A combination of two small molecule toxin inhibitors provides pancontinental preclinical efficacy against viper snakebite

This study shows that a combination of two small molecule inhibitors effectively neutralizes viper venom in vitro and prevents lethality in vivo across multiple regions.

Preclinical validation of a repurposed metal chelator as a community-based therapeutic for hemotoxic snakebite

This paper shows that the metal chelator DMPS can effectively treat hemotoxic snakebite in mice, both when given orally and in combination with antivenom.